Are Investors Being Too Paranoid About Pfizer Stock?
All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...
Pfizer (NYSE:PFE) Price Target Cut to $29.00 by Analysts at Citigroup
Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 to $29.00 in a research report issued on Tuesday,Benzinga reports. The ...
Jefferies raises Pfizer stock price target to $34, maintains Buy
Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while ...
Business Wire2d
Alloy Therapeutics Establishes Multi-Year Collaboration with Pfizer to Develop New Antibody Discovery Platform
Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...
Pfizer (NYSE:PFE) Shares Up 2.9% on Earnings Beat
Pfizer Inc. (NYSE:PFE – Get Free Report) shares traded up 2.9% on Wednesday following a stronger than expected earnings ...
Pfizer's Groundbreaking Cancer Drug Hits a Major Milestone--What It Means for Investors
BRAFTOVI's FDA Approval Sparks Hope for BRAF V600E-mutant Colorectal Cancer Patients and Sets Pfizer Up for Explosive Growth ...
Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.